medigraphic.com
A partir del año 2010, la Revista Oficial del INER cambió a NCT (Neumología y Cirugía de Tórax)

 Ver actualización

2005, Number 4

<< Back Next >>

Rev Inst Nal Enf Resp Mex 2005; 18 (4)

Endothelin system

Baltazares LM, Rodríguez CH, Ortega MJ, Sotres-Vega A, Baltazares LME

Language: Spanish
References: 61
Page: 308-320
PDF size: 212.37 Kb.


ABSTRACT

The endothelins (ETS ) family consists of three 21 aminoacid isoforms: endothelin-1 (ET-1), endothelin-2 (ET-2) and endothelin-3 (ET-3). ETS are very potent endogenous pressor agents, secreted by various cells and tissues in the human body. Of the three, endothelin-1 is the predominant isoform produced by the vascular endothelium. ET-1 induces vasoconstriction, is proinflammatory, profibrosis, and has mitogenic potential; it is also an important factor in the regulation of vascular tone and arterial vascular remodeling. These effects are mediated via two receptor types, ETA and ETB. ETA receptor is located mainly on vascular smooth muscle and is responsible for mediating vasoconstriction and proliferation. The ETB receptor is present predominantly on endothelial cells and mediates vasorelaxation for NO and prostacyclin release and also ET-1 clearance. The ET system is activated in essential hypertension, pulmonary hypertension, atherosclerosis, coronary restenosis, heart failure, idiopathic cardiomyopathy and renal failure.


REFERENCES

  1. Hickey KA, Rubanyi G, Paul RJ, Highsmith RF. Characterization of a coronary vasoconstrictor produced by cultured endothelial cells. Am J Physiol 1985;248(5 Pt 1):550-556.

  2. Yanagisawa M, Kurihara H, Kimura S, et al. A novel potent vasoconstrictor peptide produced by vascular endothelial cells. Nature 1988;332:411-415.

  3. Inoue A, Yanagisawa M, Kimura S, et al. The human endothelin family: three structurally and pharmacologically distinct isopeptides predicted by three separate genes. Proc Natl Acad Sci USA 1989;86:2864-2867.

  4. Randall MD, Douglas S, Hiley CR. Vascular activities of endothelin-1 and some alanyl substituted analogues in resistance beds of the rat. Br J Pharmacol 1989; 98:685-699.

  5. Giannessi D, del Ry S, Vitale RL. The role of endothelins and their receptors in heart failure. Pharmacol Res 2001;43:111-126.

  6. Lerman A, Edwards BS, Hallett JW, Heublein DM, Sandberg SM, Burnett JC Jr. Circulating and tissue endothelin immunoreactivity in advanced atherosclerosis. N Engl J Med 1991;325:997-1001.

  7. Emori T, Hirata Y, Ohta K, et al. Cellular mechanism of endothelin-1 release by angiotensin and vasopressin. Hypertension 1991;18:165-170.

  8. Howard PG, Plumpton C, Davenport AP. Anatomical localization and pharmacological activity of mature endothelins and their precursors in human vascular tissue. J Hypertens 1992;10:1379-1386.

  9. Firth JD, Ratcliffe PJ. Organ distribution of the three rat endothelin messenger RNAs and the effects of ischemia on renal gene expression. J Clin Invest 1992;90:1023-1031.

  10. Dupuis J, Stewart DJ, Cernacek P, Gosselin G. Human pulmonary circulation is an important site for both clearance and production of endothelin-1. Circulation 1996;94:1578-1584.

  11. Rubanyi GM, Polokoff MA. Endothelins: molecular biology, biochemistry, pharmacology, physiology, and pathophysiology. Pharmacol Rev 1994;46:325-415.

  12. Hahn AW, Resink TJ, Scott-Burden T, Powell J, Dohi Y, Buhler FR. Stimulation of endothelin mRNA and secretion in rat vascular smooth muscle cells: a novel autocrine function. Cell Regul 1990;1:649-659.

  13. Glassberg MK, Ergul A, Wanner A, Puett D. Endothelin-1 promotes mitogenesis in airway smooth muscle cells. Am J Respir Cell Mol Biol 1994;10:316-321.

  14. Sessa WC, Kaw S, Hecker M, Vane JR. The biosynthesis of endothelin-1 by human polymorphonuclear leukocytes. Biochem Biophys Res Commun 1991;174: 613-618.

  15. Ehrenreich H, Anderson RW, Fox CH, et al. Endothelins, peptides with potent vasoactive properties, are produced by human macrophages. J Exp Med 1990;172:1741-1748.

  16. Ito H, Hirata Y, Adachi S, et al. Endothelin-1 is an autocrine/ paracrine factor in the mechanism of angiotensin II-induced hypertrophy in cultured rat cardiomyocytes. J Clin Invest 1993;92:398-403.

  17. Thomas PB, Liu EC, Webb ML, Mukherjee R, Hebbar L, Spinale FG. Exogenous effects and endogenous production of endothelin in cardiac myocytes: potential significance in heart failure. Am J Physiol 1996;271(6 Pt 2):2629-2637.

  18. Fukunaga M, Fujiwara Y, Ochi S, et al. Stimulatory effect of thrombin on endothelin-1 production in isolated glomeruli and cultured mesangial cells of rats. J Cardiovasc Pharmacol 1991;17 Suppl 7:411-413.

  19. Ergul A. Endothelin-1 and endothelin receptor antagonists as potential cardiovascular therapeutic agents. Pharmacotherapy 2002;221:54-65.

  20. Levin ER. Endothelins. N Engl J Med 1995;333:356-363.

  21. Galie N, Manes A, Branzi A. The endothelin system in pulmonary arterial hypertension. Cardiovasc Res 2004;61:227-237.

  22. Remuzzi G, Benigni A. Endothelins in the control of cardiovascular and renal function. Lancet 1993;342: 589-593.

  23. Vane JR, Anggard EE, Botting RM. Regulatory functions of the vascular endothelium. N Engl J Med 1990;323:27-36.

  24. Shinmi O, Kimura S, Sawamura T, et al. Endothelin-3 is a novel neuropeptide: isolation and sequence determination of endothelin-1 and endothelin-3 in porcine brain. Biochem Biophys Res Commun 1989;164:587-593.

  25. Morawietz H, Talanow R, Szibor M, et al. Regulation of the endothelin system by shear stress in human endothelial cells. J Physiol 2000;525 Pt 3:761-770.

  26. Balakrishnan SM, Wang HD, Gopalakrishnan V, Wilson TW, McNeill JR. Effect of an endothelin antagonist on hemodynamic responses to angiotensin II. Hypertension 1996;28:806-809.

  27. Perez del Villar C, Garcia Alonso CJ, Feldstein CA, Juncos LA, Romero JC. Role of endothelin in the pathogenesis of hypertension. Mayo Clin Proc 2005;80:84-96.

  28. Galron R, Bdolah A, Kochva E, Wollberg Z, Kloog Y, Sokolovsky M. Kinetic and cross-linking studies indicate different receptors for endothelins and sarafotoxins in the ileum and cerebellum. FEBS Lett 1991;283:11-14.

  29. Watanabe H, Miyazaki H, Kondoh M, et al. Two distinct types of endothelin receptors are present on chick cardiac membranes. Biochem Biophys Res Commun 1989;161:1252-1259.

  30. Masaki T. Historical review: Endothelin. Trends Pharmacol Sci 2004;25:219-224.

  31. Dupuis J, Jasmin JF, Prie S, Cernacek P. Importance of local production of endothelin-1 and of the ET(B) receptor in the regulation of pulmonary vascular tone. Pulm Pharmacol Ther 2000;13:135-140.

  32. Abassi ZA, Tate JE, Golomb E, Keiser HR. Role of neutral endopeptidase in the metabolism of endothelin. Hypertension 1992;20:89-95.

  33. Fagny C, Michel A, Nortier J, Deschodt-Lanckman M. Enzymatic degradation of endothelin-1 by activated human polymorphonuclear neutrophils. Regul Pept 1992;42:27-37.

  34. Karne S, Jayawickreme CK, Lerner MR. Cloning and characterization of an endothelin-3 specific receptor (ETC receptor) from Xenopus laevis dermal melanophores. J Biol Chem 1993;268:19126-19133.

  35. Morawietz H, Szibor M, Goettsch W, et al. Deloading of the left ventricle by ventricular assist device normalizes increased expression of endothelin ET(A) receptors but not endothelin-converting enzyme-1 in patients with end-stage heart failure. Circulation 2000;102 (19 Suppl 3):188-193.

  36. Quehenberger P, Exner M, Sunder-Plassmann R, et al. Leptin induces endothelin-1 in endothelial cells in vitro. Circ Res 2002; 90:711-718.

  37. Malek A, Izumo S. Physiological fluid shear stress causes down regulation of endothelin-1 mRNA in bovine aortic endothelium. Am J Physiol 1992;263(2 Pt 1):389-396.

  38. Savoia C, Schiffrin EL. Significance of recently identified peptides in hypertension: endothelin, natriuretic peptides, adrenomedullin, leptin. Med Clin North Am 2004;88:39-62.

  39. Haynes WG, Ferro CE, Webb DJ. Physiologic role of endothelin in maintenance of vascular tone in humans. J Cardiovasc Pharmacol 1995;26 Suppl 3:183-185.

  40. Luscher TF, Barton M. Endothelins and endothelin receptor antagonists: therapeutic considerations for a novel class of cardiovascular drugs. Circulation 2000;102:2434-2440.

  41. Seccia TM, Belloni AS, Kreutz R, et al. Cardiac fibrosis occurs early and involves endothelin and AT-1 receptors in hypertension due to endogenous angiotensin II. J Am Coll Cardiol 2003;41:666-673.

  42. Jozsef L, Khreiss T, Fournier A, Chan JS, Filep JG. Extracellular signal-regulated kinase plays an essential role in endothelin-1-induced homotypic adhesion of human neutrophil granulocytes. Br J Pharmacol 2002;135:1167-1174.

  43. Belloni AS, Rossi GP, Andreis PG, et al. Endothelin adrenocortical secretagogue effect is mediated by the B receptor in rats. Hypertension 1996;27:1153-1159.

  44. Ishikawa T, Yanagisawa M, Kimura S, Goto K, Masaki T. Positive inotropic action of novel vasoconstrictor peptide endothelin on guinea pig atria. Am J Physiol 1988;255(4 Pt 2): 970-973.

  45. Yanagisawa M, Masaki T. Endothelin, a novel endothelium-derived peptide. Pharmacological activities, regulation and possible roles in cardiovascular control. Biochem Pharmacol 1989;38:1877-1883.

  46. Yang Z, Bauer E, von Segesser L, Stulz P, Turina M, Luscher TF. Different mobilization of calcium in endothelin-1-induced contractions in human arteries and veins: effect of calcium antagonists. J Cardiovasc Pharmacol 1990;16:654-660.

  47. Haynes WG, Ferro CJ, O’Kane KP, Somerville D, Lomax CC, Webb DJ. Systemic endothelin receptor blockade decreases peripheral vascular resistance and blood pressure in human. Circulation 1996;93:1860-1870.

  48. Josko J, Gwozdz B, Hendryk S, Jedrzejowska-Szypulka H, Slowinski J, Jochem J. Expression of vascular endothelial growth factor (VEGF) in rat brain after subarachnoid haemorrhage and endothelin receptor blockade with BQ-123. Folia Neuropathol 2001;39:243-251.

  49. Mortensen LH, Fink GD. Salt-dependency of endothelin-induced chronic hypertension in conscious rats. Hypertension 1992;19(6 Pt 1):549-554.

  50. Lerman A, Hildebrand FL Jr, Margulies KB, et al. Endothelin: a new cardiovascular regulatory peptide. Mayo Clin Proc 1990;65:1441-1455.

  51. Goraca A. New views on the role of endothelin. Endocr Regul 2002;36:161-167.

  52. Lerman A, Holmes DR Jr, Bell MR, Garratt KN, Nishimura RA, Burnett JC Jr. Endothelin in coronary endothelial dysfunction and early atherosclerosis in humans. Circulation 1995;92:2426-2431.

  53. Best PJ, Lerman LO, Romero JC, Richardson D, Holmes DR Jr, Lerman A. Coronary endothelial function is preserved with chronic endothelin receptor antagonism in experimental hypercholesterolemia in vitro. Arterioscler Thromb Vasc Biol 1999;19:2769-2775.

  54. Mathew V, Hasdai D, Lerman A. The role of endothelin in coronary atherosclerosis. Mayo Clin Proc 1996;71: 769-777.

  55. Piuhola J, Szokodi I, Kinnunen P, et al. Endothelin-1 contributes to the Frank-Starling response in hypertrophic rat hearts. Hypertension 2003;41:93-98.

  56. Geller L, Merkely B, Szokodi I, et al. Electrophysiological effects of intrapericardial infusion of endothelin-1. Pacing Clin Electrophysiol 1998;21(1 Pt 2):151-156.

  57. Luscher TF, Enseleit F, Pacher R, et al. Hemodynamic and neurohumoral effects of selective endothelin A (ET(A)) receptor blockade in chronic heart failure: the heart failure ET(A) Receptor Blockade Trial (HEAT). Circulation 2002;106:2666-2672.

  58. Fagan KA, McMurtry IF, Rodman DM. Role of endothelin-1 in lung disease. Respir Res 2001:2;90-101.

  59. Giaid A, Michel RP, Stewart DJ, Sheppard M, Corrin B, Hamid Q. Expression of endothelin-1 in lungs of patients with cryptogenic fibrosing alveolitis. Lancet 1993;341:1550-1554.

  60. Balakrishnan S, Pandhi P. Endothelins: a brief review. Indian J Pharmacol 1997;29:281-288.

  61. * Nota: Para consultar las demás referencias, 73 en total, favor de solicitarlas al Dr. Baltazares al correo electrónico: balmlipp@yahoo.com.mx




2020     |     www.medigraphic.com